Show simple item record

dc.contributor.authorLee, AWen_US
dc.contributor.authorNg, WTen_US
dc.contributor.authorPan, JJen_US
dc.contributor.authorPoh, SSen_US
dc.contributor.authorAhn, YCen_US
dc.contributor.authorAlHussain, Hen_US
dc.contributor.authorCorry, Jen_US
dc.contributor.authorGrau, Cen_US
dc.contributor.authorGrégoire, Ven_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorHu, CSen_US
dc.contributor.authorKwong, DLen_US
dc.contributor.authorLangendijk, JAen_US
dc.contributor.authorLe, QTen_US
dc.contributor.authorLee, NYen_US
dc.contributor.authorLin, JCen_US
dc.contributor.authorLu, TXen_US
dc.contributor.authorMendenhall, WMen_US
dc.contributor.authorO'Sullivan, Ben_US
dc.contributor.authorOzyar, Een_US
dc.contributor.authorPeters, LJen_US
dc.contributor.authorRosenthal, DIen_US
dc.contributor.authorSoong, YLen_US
dc.contributor.authorTao, Yen_US
dc.contributor.authorYom, SSen_US
dc.contributor.authorWee, JTen_US
dc.coverage.spatialIrelanden_US
dc.date.accessioned2018-02-16T10:14:19Z
dc.date.issued2018-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29153464en_US
dc.identifierS0167-8140(17)32686-5en_US
dc.identifier.citationRadiother Oncol, 2018, 126 (1), pp. 25 - 36en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1165
dc.identifier.eissn1879-0887en_US
dc.identifier.doi10.1016/j.radonc.2017.10.032en_US
dc.description.abstractPURPOSE: Target delineation in nasopharyngeal carcinoma (NPC) often proves challenging because of the notoriously narrow therapeutic margin. High doses are needed to achieve optimal levels of tumour control, and dosimetric inadequacy remains one of the most important independent factors affecting treatment outcome. METHOD: A review of the available literature addressing the natural behaviour of NPC and correlation between clinical and pathological aspects of the disease was conducted. Existing international guidelines as well as published protocols specified by clinical trials on contouring of clinical target volumes (CTV) were compared. This information was then summarized into a preliminary draft guideline which was then circulated to international experts in the field for exchange of opinions and subsequent voting on areas with the greatest controversies. RESULTS: Common areas of uncertainty and variation in practices among experts experienced in radiation therapy for NPC were elucidated. Iterative revisions were made based on extensive discussion and final voting on controversial areas by the expert panel, to formulate the recommendations on contouring of CTV based on optimal geometric expansion and anatomical editing for those structures with substantial risk of microscopic infiltration. CONCLUSION: Through this comprehensive review of available evidence and best practices at major institutions, as well as interactive exchange of vast experience by international experts, this set of consensus guidelines has been developed to provide a practical reference for appropriate contouring to ensure optimal target coverage. However, the final decision on the treatment volumes should be based on full consideration of individual patients' factors and facilities of an individual centre (including the quality of imaging methods and the precision of treatment delivery).en_US
dc.format.extent25 - 36en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectClinical target volume (CTV)en_US
dc.subjectDelineationen_US
dc.subjectGross target volume (GTV)en_US
dc.subjectGuidelineen_US
dc.subjectNasopharyngeal carcinomaen_US
dc.subjectCarcinomaen_US
dc.subjectConsensusen_US
dc.subjectHumansen_US
dc.subjectNasopharyngeal Carcinomaen_US
dc.subjectNasopharyngeal Neoplasmsen_US
dc.subjectRadiotherapy Planning, Computer-Assisteden_US
dc.titleInternational guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-10-25en_US
rioxxterms.versionofrecord10.1016/j.radonc.2017.10.032en_US
rioxxterms.licenseref.startdate2018-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfRadiother Oncolen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume126en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record